PAX6 and breast carcinoma: Analysis performed using the UCSC Xena platform (https://xena.ucsc.edu/compare-tissue/), based on data from the TCGA Breast Cancer (BRCA) cohort and accessed on 28 March 2025, revealed no significant differences in overall survival based on PAX6 expression levels (Figure 1C).